Results 201 to 210 of about 894,820 (296)

Mycophenolate Mofetil Treatment Reduces the Risk of Treatment Escalation Due to Vascular Complications in Limited Cutaneous Systemic Sclerosis: Emulation of a Target Trial From the Italian Rheumatology Society SPRING Registry

open access: yesArthritis Care &Research, EarlyView.
Objective Mycophenolate mofetil (MMF) use in limited cutaneous systemic sclerosis (lcSSc) is relatively uncommon because of the lower fibrotic burden and the predominance of vascular complications. In vitro observations and clinical data from transplanted patients suggest a protective effect of MMF on endothelial function.
Enrico De Lorenzis   +77 more
wiley   +1 more source

Prevalence of Systemic Lupus Erythematosus in Australia, 2010–2022: A Population‐Based Study Using Linked National Administrative Health Data

open access: yesArthritis Care &Research, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a heterogenous inflammatory condition with widely varying global prevalence estimates. The frequency of SLE in the general population of Australia has been reported to be notably lower than contemporary estimates in countries such as the United States or United Kingdom, at 19 to 39 per 100,000 as opposed ...
Lucinda Roper   +7 more
wiley   +1 more source

Formal and informal social care in people with Rheumatic and Musculoskeletal diseases: a cross‐sectional multicentre survey

open access: yesArthritis Care &Research, Accepted Article.
Introduction Rheumatic and musculoskeletal diseases(RMDs) are leading causes of physical disability, necessitating support with activities of daily living(ADLs). This study describes social care received by patients with RMDs in two disperate regions of England: Salford(urban) and Norfolk(rural).
Mehreen Somro   +6 more
wiley   +1 more source

Integrating Patient‐Reported Quality Measures in Systemic Lupus Erythematosus: Development of the American College of Rheumatology Implementation Guide

open access: yesArthritis Care &Research, EarlyView.
Objective To support high‐quality, patient‐centered care for systemic lupus erythematosus (SLE), the American College of Rheumatology (ACR) developed evidence‐based measures incorporating clinical and patient‐reported outcome measures (PROMs). Using the Consolidated Framework for Implementation Research (CFIR), we conducted semistructured interviews ...
Catherine Nasrallah   +13 more
wiley   +1 more source

Mucocutaneous disease activity and damage accrual in systemic lupus erythematosus: analyses from the Asia‐Pacific Lupus Collaboration longitudinal cohort study

open access: yesArthritis Care &Research, Accepted Article.
Objective This research article aims to describe the prevalence, associations and health‐related quality‐of‐life (HRQoL) impact of mucocutaneous features of SLE. Methods Data from the Asia‐Pacific Lupus Collaboration cohort were analysed (2013‐2021). Mucocutaneous activity (MC‐A) items were rash, alopecia and mucosal ulcers; defined by the SLEDAI‐2K ...
Amanda M Saracino   +42 more
wiley   +1 more source

Home - About - Disclaimer - Privacy